Your browser doesn't support javascript.
loading
The radiologically isolated syndrome: revised diagnostic criteria.
Lebrun-Frénay, Christine; Okuda, Darin T; Siva, Aksel; Landes-Chateau, Cassandre; Azevedo, Christina J; Mondot, Lydiane; Carra-Dallière, Clarisse; Zephir, Helene; Louapre, Celine; Durand-Dubief, Françoise; Le Page, Emmanuelle; Bensa, Caroline; Ruet, Aurélie; Ciron, Jonathan; Laplaud, David A; Casez, Olivier; Mathey, Guillaume; de Seze, Jerome; Zeydan, Burcu; Makhani, Naila; Tutuncu, Melih; Levraut, Michael; Cohen, Mikael; Thouvenot, Eric; Pelletier, Daniel; Kantarci, Orhun H.
Afiliación
  • Lebrun-Frénay C; Neurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.
  • Okuda DT; Neuroinnovation Program, Multiple Sclerosis, and Neuroimmunology Imaging Program, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Siva A; Department of Neurology, Istanbul University Cerrahpasa School of Medicine, 34098 Istanbul, Turkey.
  • Landes-Chateau C; Neurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.
  • Azevedo CJ; Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
  • Mondot L; Neurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.
  • Carra-Dallière C; Neurology MS Clinic, Montpellier University Hospital, 34295 Montpellier, France.
  • Zephir H; University of Montpellier (MUSE), 34295 Montpellier, France.
  • Louapre C; Inserm UMR-S 1172 LilNcog, Lille University, Lille University Hospital Precise, 59000 Lille, France.
  • Durand-Dubief F; Department of Neurology, Sorbonne University, AP-HP, Pitié-Salpêtrière Hospital, 75013 Paris, France.
  • Le Page E; Neurology MS Clinic, Neurological Hospital Pierre Wertheimer, Lyon University Hospital, 69500 Lyon/Bron, France.
  • Bensa C; Neurology MS Clinic Rennes, Clinical Investigation Centre CIC-P 1414, Rennes University Hospital, 35000 Rennes, France.
  • Ruet A; Neurology, Rothschild Foundation, 75019 Paris, France.
  • Ciron J; Neurology MS Clinic Bordeaux, University Hospital, 33000 Bordeaux, France.
  • Laplaud DA; Neurocentre Magendie, Bordeaux University, INSERM, U1215, 33000 Bordeaux, France.
  • Casez O; Neurology MS Clinic, Toulouse University Hospital, 31300 Toulouse, France.
  • Mathey G; Infinity, INSERM UMR1291, CNRS UMR5051, Toulouse III University, 31300 Toulouse, France.
  • de Seze J; Neurology, Nantes University Hospital, CIC1314 INSERM, 44000 Nantes, France.
  • Zeydan B; CR2TI INSERM U1064, Nantes University, 44000 Nantes, France.
  • Makhani N; Neurology MS Clinic Grenoble, Grenoble Alpes University Hospital, 38700 Grenoble, France.
  • Tutuncu M; T-RAIG, TIMC-IMAG, Grenoble Alpes University, 38700 Grenoble, France.
  • Levraut M; Neurology, Nancy University Hospital, 54000 Nancy, France.
  • Cohen M; Vandoeuvre-Lès-Nancy, Lorraine University, EA 4360 APEMAC, 54000 Nancy, France.
  • Thouvenot E; Clinical Investigation Center, Neurology, Strasbourg University Hospital, INSERM 1434, 67200 Strasbourg, France.
  • Pelletier D; Neurology and Radiology, Mayo Clinic, Rochester, MN 55905, USA.
  • Kantarci OH; Pediatrics and Neurology, Yale School of Medicine, New Haven, CT 06510, USA.
Brain ; 146(8): 3431-3443, 2023 08 01.
Article en En | MEDLINE | ID: mdl-36864688
ABSTRACT
The radiologically isolated syndrome (RIS) was defined in 2009 as the presence of asymptomatic, incidentally identified demyelinating-appearing white matter lesions in the CNS within individuals lacking symptoms typical of multiple sclerosis (MS). The RIS criteria have been validated and predict the transition to symptomatic MS reliably. The performance of RIS criteria that require fewer MRI lesions is unknown. 2009-RIS subjects, by definition, fulfil three to four of four criteria for 2005 dissemination in space (DIS) and subjects fulfilling only one or two lesions in at least one 2017 DIS location were identified within 37 prospective databases. Univariate and multivariate Cox regression models were used to identify predictors of a first clinical event. Performances of different groups were calculated. Seven hundred and forty-seven subjects (72.2% female, mean age 37.7 ± 12.3 years at the index MRI) were included. The mean clinical follow-up time was 46.8 ± 45.4 months. All subjects had focal T2 hyperintensities suggestive of inflammatory demyelination on MRI; 251 (33.6%) fulfilled one or two 2017 DIS criteria (designated as Groups 1 and 2, respectively), and 496 (66.4%) fulfilled three or four 2005 DIS criteria representing 2009-RIS subjects. Group 1 and 2 subjects were younger than the 2009-RIS group and were more likely to develop new T2 lesions over time (P < 0.001). Groups 1 and 2 were similar regarding survival distribution and risk factors for transition to MS. At 5 years, the cumulative probability for a clinical event was 29.0% for Groups 1 and 2 compared to 38.7% for 2009-RIS (P = 0.0241). The presence of spinal cord lesions on the index scan and CSF-restricted oligoclonal bands in Groups 1-2 increased the risk of symptomatic MS evolution at 5 years to 38%, comparable to the risk of development in the 2009-RIS group. The presence of new T2 or gadolinium-enhancing lesions on follow-up scans independently increased the risk of presenting with a clinical event (P < 0.001). The 2009-RIS subjects or Groups 1 and 2 with at least two of the risk factors for a clinical event demonstrated better sensitivity (86.0%), negative predictive value (73.1%), accuracy (59.8%) and area under the curve (60.7%) compared to other criteria studied. This large prospective cohort brings Class I evidence that subjects with fewer lesions than required in the 2009 RIS criteria evolve directly to a first clinical event at a similar rate when additional risk factors are present. Our results provide a rationale for revisions to existing RIS diagnostic criteria.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Desmielinizantes / Esclerosis Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Brain Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Desmielinizantes / Esclerosis Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Brain Año: 2023 Tipo del documento: Article País de afiliación: Francia